Literature DB >> 9683613

Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene.

H R Waterham1, F A Wijburg, R C Hennekam, P Vreken, B T Poll-The, L Dorland, M Duran, P E Jira, J A Smeitink, R A Wevers, R J Wanders.   

Abstract

Smith-Lemli-Opitz syndrome is a frequently occurring autosomal recessive developmental disorder characterized by facial dysmorphisms, mental retardation, and multiple congenital anomalies. Biochemically, the disorder is caused by deficient activity of 7-dehydrocholesterol reductase, which catalyzes the final step in the cholesterol-biosynthesis pathway-that is, the reduction of the Delta7 double bond of 7-dehydrocholesterol to produce cholesterol. We identified a partial transcript coding for human 7-dehydrocholesterol reductase by searching the database of expressed sequence tags with the amino acid sequence for the Arabidopsis thaliana sterol Delta7-reductase and isolated the remaining 5' sequence by the "rapid amplification of cDNA ends" method, or 5'-RACE. The cDNA has an open reading frame of 1,425 bp coding for a polypeptide of 475 amino acids with a calculated molecular weight of 54.5 kD. Heterologous expression of the cDNA in the yeast Saccharomyces cerevisiae confirmed that it codes for 7-dehydrocholesterol reductase. Chromosomal mapping experiments localized the gene to chromosome 11q13. Sequence analysis of fibroblast 7-dehydrocholesterol reductase cDNA from three patients with Smith-Lemli-Opitz syndrome revealed distinct mutations, including a 134-bp insertion and three different point mutations, each of which was heterozygous in cDNA from the respective parents. Our data demonstrate that Smith-Lemli-Opitz syndrome is caused by mutations in the gene coding for 7-dehydrocholesterol reductase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683613      PMCID: PMC1377322          DOI: 10.1086/301982

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES.

Authors:  D W SMITH; L LEMLI; J M OPITZ
Journal:  J Pediatr       Date:  1964-02       Impact factor: 4.406

2.  A new face for an old syndrome.

Authors:  R I Kelley
Journal:  Am J Med Genet       Date:  1997-01-31

3.  Smith-Lemli-Opitz syndrome: deficient delta 7-reductase activity in cultured skin fibroblasts and chorionic villus fibroblasts and its application to pre- and postnatal detection.

Authors:  R J Wanders; G J Romeijn; F Wijburg; R C Hennekam; J de Jong; R A Wevers; G Dacremont
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

4.  Smith-Lemli-Opitz syndrome-type II: multiple congenital anomalies with male pseudohermaphroditism and frequent early lethality.

Authors:  C J Curry; J C Carey; J S Holland; D Chopra; R Fineman; M Golabi; S Sherman; R A Pagon; J Allanson; S Shulman
Journal:  Am J Med Genet       Date:  1987-01

5.  Modes of DAPI banding and simultaneous in situ hybridization.

Authors:  H H Heng; L C Tsui
Journal:  Chromosoma       Date:  1993-05       Impact factor: 4.316

6.  Holoprosencephaly in RSH/Smith-Lemli-Opitz syndrome: does abnormal cholesterol metabolism affect the function of Sonic Hedgehog?

Authors:  R L Kelley; E Roessler; R C Hennekam; G L Feldman; K Kosaki; M C Jones; J C Palumbos; M Muenke
Journal:  Am J Med Genet       Date:  1996-12-30

7.  Smith-Lemli-Opitz syndrome in a female with a de novo, balanced translocation involving 7q32: probable disruption of an SLOS gene.

Authors:  M Wallace; R T Zori; T Alley; E Whidden; B A Gray; C A Williams
Journal:  Am J Med Genet       Date:  1994-05-01

8.  Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome.

Authors:  G S Tint; G Salen; A K Batta; S Shefer; M Irons; E R Elias; D N Abuelo; V P Johnson; M Lambert; R Lutz
Journal:  J Pediatr       Date:  1995-07       Impact factor: 4.406

9.  Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol delta 7-reductase.

Authors:  E Lecain; X Chenivesse; R Spagnoli; D Pompon
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

10.  Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes.

Authors:  S Shefer; G Salen; A K Batta; A Honda; G S Tint; M Irons; E R Elias; T C Chen; M F Holick
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

View more
  62 in total

1.  Smith-Lemli-Opitz syndrome: molecular-genetic analysis of ten families.

Authors:  L Kozák; H Francová; E Hrabincová; D Procházková; V Jüttnerová; V Bzdúch; P Simek
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

Review 2.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

Review 3.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

Review 4.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

5.  Identification of a sterol Delta7 reductase gene involved in desmosterol biosynthesis in Mortierella alpina 1S-4.

Authors:  Shuo Zhang; Eiji Sakuradani; Sakayu Shimizu
Journal:  Appl Environ Microbiol       Date:  2007-01-12       Impact factor: 4.792

6.  Identification of Environmental Quaternary Ammonium Compounds as Direct Inhibitors of Cholesterol Biosynthesis.

Authors:  Josi Herron; Rosalyn C Reese; Keri A Tallman; Rohini Narayanaswamy; Ned A Porter; Libin Xu
Journal:  Toxicol Sci       Date:  2016-02-26       Impact factor: 4.849

7.  Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome.

Authors:  Elaine Tierney; Sandra K Conley; Halima Goodwin; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

8.  Challenging behavior in Smith-Lemli-Opitz syndrome: initial test of biobehavioral influences.

Authors:  Kurt A Freeman; Rose Eagle; Louise S Merkens; Darryn Sikora; Kersti Pettit-Kekel; Mina Nguyen-Driver; Robert D Steiner
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

9.  Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease.

Authors:  C Mueller; S Patel; M Irons; K Antshel; G Salen; G S Tint; C Bay
Journal:  Am J Med Genet A       Date:  2003-11-15       Impact factor: 2.802

10.  Enhanced placental cholesterol efflux by fetal HDL in Smith-Lemli-Opitz syndrome.

Authors:  Katie T Jenkins; Louise S Merkens; Matthew R Tubb; Leslie Myatt; W Sean Davidson; Robert D Steiner; Laura A Woollett
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.